3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
4
Multiple Myeloma
2
Vaccinia
1
Transplant-Related Hematologic Malignancy
1
Recurrence
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Glioma
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Nivolumab
37
pembrolizumab
30
cabozantinib
27
Specimen Handling
25
Magnetic Resonance Spectroscopy
22
Ipilimumab
20
lenvatinib
16
Axitinib
15
belzutifan
13
CTLA-4 Antigen
10
Sunitinib
9
Biopsy
9
Radiosurgery
8
atezolizumab
7
Immunoglobulin G
5
toripalimab
4
fludarabine
4
avelumab
4
aldesleukin
4
Everolimus
4
Disulfides
4
Cyclophosphamide
4
zimberelimab
3
tivozanib
3
spartalizumab
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
90 days
×
Clear all
No trials found.